Abstract: An antibody having a higher function targeting a CD73 antigen, and more specifically, an antibody for cancer treatment having a higher activity. The antibody or a human-type antibody derivative that has a binding activity to a CD73 antigen and activates T cells having a toxic activity to cancer cells, and includes complementarity determining regions of any combination of heavy and light chains each having a specific amino acid sequence.

Abstract: A peptide vaccine complexed so that the peptide vaccine can be delivered specifically to the surface of specific immune cells and a method for delivering a peptide vaccine specifically to the surface of specific immune cells. The peptide vaccine is combined with an IgG binding peptide capable of binding to an IgG that is an agonist against molecules on the surface of specific immune cells such as dendritic cells.

Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.

Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.

Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.

Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.

Abstract: The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.

Abstract: An object of the present invention is to introduce a sample solution into the minute and hydrophobic inside of a reactor for a pretreatment while avoiding bubble formation. According to the present invention, a reactor that has at least one portion having a width of 90% or less of its whole width between an inflow opening and an outflow opening is constructed on a planar substrate.

Abstract: The expression and the phosphorylation level of a target protein are determined without performing complicated operations involving risk; the expression and the phosphorylation level of the target protein are simultaneously determined, by separating and detecting the specific protein from other proteins different from the specific protein, and by specifically detecting a phosphorylated residue of the identified target protein; and finally a ratio of the target protein phosphorylated is calculated to obtain the phosphorylation ratio of the protein.

Abstract: The object of the present invention is to promote the efficiency and simplify a sample pretreatment step for analysis of molecules contained in the sample. In the present invention, a plurality of various enzymes necessary for pretreatment of sample for analysis of various molecules contained in the sample are immobilized on a solid phase separately for each kind of enzyme, and the enzyme reactions are carried out simultaneously. That is, a sample is reacted with plural kinds of enzymes under the same conditions, and contamination caused by the enzyme reactions is inhibited and the sample is subjected to a given pretreatment.

Abstract: It is an object of the present invention to conduct function analysis of proteins arranged with high density on a solid phase in a high-throughput manner, regardless of protein varieties. The present invention is characterized in that it immobilizes target proteins on a substrate while maintaining the structures and the functions thereof, and that it carries out interaction analysis of such proteins. For example, target proteins are prepared in a state where one end of each protein is fused to a peptide as a tag or to a polypeptide by genetic engineering methods. Then, the target proteins are bonded to the substrate via a layer formed thereon, comprising anti-tag antibodies. The target proteins are arrayed while they are maintained in a liberated state on a solid phase, and the interaction analysis is carried out. According to the present invention, the interaction analysis of target proteins can be carried out without affecting the unstable structures and the functions thereof.